Nearly two dozen health and consumer advocacy groups are urging the Italian health minister not to replace the head of the Italian medicines agency, who was widely credited with getting the World Health Assembly last May to adopt a resolution for seeking transparency in drug pricing.

In a letter, the groups argued that Dr. Luca Li Bassi, who for the past year has been director general of Agenzia Italiana del Farmaco, or AIFA, is a skilled policy maker who has successfully pursued public health goals, such as championing strategies to make new medical inventions more affordable, and should be allowed to remain in his job.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy